Clinical trials: Relapsed
Relapsed or Refractory B-cell Lymphoma
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
PD1 pathway is critical in determining the response to CAR T cell therapy. Emerging data suggested that Inhibition of PD1 could enhance the efficacy of CAR T cell therapy.
- Trial name
- NCT03208556
- Testing
- iPD1 CD19 eCAR T cells, Fludarabine and cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University
Acute Myeloid Leukemia
Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML
This project is a prospective, multicenter, randomized controlled clinical study. The subjects were refractory / relapsed AML patients aged ≤ 60 years diagnosed by bone marrow cell morphology, immunology, genetics and therapeutic…
- Trial name
- NCT06133556
- Testing
- MCBC regimen, Bu/Cy regimen
- Volunteers
- 237 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphoma, Relapse
Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
Because Primary Central Nervous System Lymphoma (PCNSL) are mainly diffuse large B-cell lymphoma of the activated B cells (ABC) type, the investigators hypothesize that the synergy of lenalidomide with rituximab shown in systemic…
- Trial name
- REVRI (NCT01956695)
- Testing
- Lenalidomide, Rituximab
- Where
- 12 sites in France
- Volunteers
- 45 people
- Sponsor
- Institut Curie
Lymphoma
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00005601
- Testing
- rituximab, cisplatin, cytarabine
- Where
- 21 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma
A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma
This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.
- Trial name
- NCT02079519
- Testing
- Bevacizumab
- Where
- 4 sites in Austria
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Adult Favorable Prognosis Hodgkin Lymphoma, Adult Lymphocyte Depletion Hodgkin Lymphoma
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
This phase II trial is studying how well vorinostat works in treating patients with relapsed or refractory advanced Hodgkin's lymphoma.
- Conditions
- Adult Favorable Prognosis Hodgkin Lymphoma, Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma
- Trial name
- NCT00132028
- Testing
- vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
AML, MDS
Study of APVO436 in Patients With AML or MDS
The primary objective of the Phase 1 part of the study is to determine the recommended dose of APVO436 administered intravenously to patients with AML or MDS.
- Trial name
- NCT03647800
- Testing
- APVO436
- Where
- 12 sites in United States
- Volunteers
- 136 people
- Sponsor
- Aptevo Research and Development LLC
B-ALL
KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 injection for patients with relapsed/refractory B-Cell acute lymphoblastic…
- Trial name
- NCT07246707
- Testing
- KSV01 Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Primary Central Nervous System Lymphoma
IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL
This is a multicenter, single-arm, prospective phase II study to evaluate the efficacy and safety of a novel combination regimen for relapsed/refractory PCNSL.
- Trial name
- NCT04066920
- Testing
- IBER salvage chemotherapy followed by ibrutinib maintenance therapy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Deok-Hwan Yang
Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will…
- Trial name
- NCT02956382
- Testing
- Ibrutinib, Venetoclax
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Georgetown University
Chronic Hepatitis b, Hepatitis B Reactivation
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
We will conduct a phase 4, multicenter, open-label trial at 8 academic centers in Taiwan. Chronic hepatitis B patients receiving oral antiviral therapy (entecavir [ETV], tenofovir disoproxil fumarate [TDF]) for at least 1 year…
- Trial name
- CHANGE (NCT04496882)
- Testing
- Vemlidy
- Where
- 8 sites in Taiwan
- Volunteers
- 260 people
- Sponsor
- National Taiwan University Hospital
Acute Myeloid Leukemia
TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission
Acute myeloid leukemia (AML) is a serious blood cancer that mainly affects older adults. For patients who achieve their first complete remission (CR1), allogeneic hematopoietic stem cell transplantation (HSCT) may provide a…
- Trial name
- TBF-AML (NCT07563920)
- Testing
- Thiotepa, Busulfan (BU), Fludarabine
- Volunteers
- 93 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lymphoma
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002982
- Testing
- filgrastim, carboplatin, carmustine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ewing Sarcoma
RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT
The goal of this clinical research study is to learn if new anticancer drugs or drug combinations can help to control relapsed/refractory ES, DSRCT, or SRCS.
- Trial name
- NCT07781891
- Testing
- LX-101
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
The purpose of this study is to determine whether giving linvoseltamab with lenalidomide during maintenance treatment to participants with multiple myeloma will: 1.
- Trial name
- NCT06910124
- Testing
- Linvoseltamab, Lenalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Dickran Kazandjian, MD
Multiple Myeloma in Relapse, Multiple Myeloma
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of this study are to learn about the safety of different doses of MK-4002 and how well people…
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
- Trial name
- NCT04184050
- Testing
- MK-4002
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 100 people
- Sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Small Cell Lung Cancer Recurrent
S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer
The purpose of this study is to assess the efficacy and safety of S1 combination with Anlotinib in patients with small cell lung cancer whose cancer has progression or recurrence after at least one standard chemotherapy.
- Trial name
- NCT03823118
- Testing
- S1/Anlotinib
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Taizhou Hospital
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR).
- Trial name
- NCT05144841
- Testing
- Zilovertamab vedotin
- Where
- 71 sites in United States, Canada and 15 more
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
This phase I trial studies the side effects and best dose of vorinostat when given together with pembrolizumab in treating patients with diffuse large B-cell lymphoma, follicular lymphoma, or Hodgkin lymphoma that has come back…
- Conditions
- Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL, Recurrent Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03150329
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- City of Hope Medical Center
Hodgkin's Disease, Lymphoma
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
Primary Objective: To determine the safety and efficacy of Campath-1H (Alemtuzumab) in patients with relapsed and resistant classical Hodgkin's lymphoma. Secondary Objectives: 1.
- Trial name
- NCT00129753
- Testing
- Alemtuzumab (Campath-1H)
- Volunteers
- healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.